Skip to main content

Advertisement

Table 1 Patient characteristics at baseline

From: Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry

  Etanercept Tocilizumab 1. Biologic Tocilizumab switcher IL-1 inhibitors (anakinra or Canakinumab) 1. Biologic IL-1 inhibitors (anakinra or canakinumab) switcher
Patient numbers 143 37 34 17 43 (30 + 13)
Gender (female) 72 (50.3%) 20 (54%) 17 (50%) 6 (35%) 22 (52%)
Age at onset (years)
 mean +/-SD 5.0 +/- 3.8 5.8 +/- 4.3 3.7 +/- 3.4 6.8 +/- 4.7 4.5 +/- 3.2
 median (IQR) 4.1 (2.3; 6.4) 4.9 (2.2; 8.1) 2.6 (1.4; 4.4) 5.2 (3.5; 11.2) 3.7 (247; 5.3)
Age at bDMARD start (years)
 mean +/- SD 9.4 +/- 5.0 7.8 +/- 4.9 10.7 +/- 4.4 9.2 +/- 4.8 9.6 +/- 4.6
 median (IQR) 8.2 (5.3; 13.0) 7.2 (3.2; 12.0) 10.6 (8.3; 13.7) 8.1 (5.1; 13.3) 8.4 (5.7; 13.2)
Disease duration (years)
 mean +/- SD 4.5 +/- 4.1 2.0 +/- 2.6 7.0 +/- 4.3 4.1 +/- 4.0 5.1 +/- 3.9
 median (IQR) 3.3 (1.1; 6.6)) 0.8 (0.3; 2.5) 7.4 (3.6; 9.8) 2.8 (0.6; 7.0) 5.2 (1.5; 8.7)
Pretreatment oral
 steroids 143 (100%) 37 (100%) 34 (100%) 11 (65%) 41 (95%)
 steroid pulse therapy 24 (16.8%) 10 (27%) 6 (18%) 5 (29%) 12 (28%)
 i.a. steroids 42 (29.4%) 4 (11%) 7 (21%) 0 10 (23%)
 MTX 126 (88.1%) 29 (78%) 31 (91%) 8 (47%) 36 (83%)
 other DMARDs 136 (95.1%) 6 (16%) 12 (35%) 3 (18%) 20 (47%)
 biologics 2 (1.4%) 0 34 (100%) 0 39 (65.0%)
 abatacept 0 0 1 (3%) 0 0
 adalimumab 0 0 3 (9%) 0 3 (5.0%)
 anakinra 2 (1.4%) 0 18 (53%) 0 n.a
 canakinumab 0 0 2 (6%) 0 n.a.
 etanercept 0 0 27 (79%) 0 32 (74.0%)
 infliximab 0 0 1 (3%) 0 0
 tocilizimab 0 0 0 0 9 (21%)
Concomitant treatment at enrolment
 steroids 118 (82.5%) 19 (51%) 12 (34%) 8 (47%) 19 (44%)
 MTX 116 (81.1%) 25 (68%) 21 (62%) 5 (29%) 18 (42%)
 other DMARDs 34 (23.8%) 3 (8%) 3 (9%) 2 (12%) 4 (10%)
Systemic manifestations at enrolment
 fever 1/13 (7.7%) 16/30 (53%) 7/32 (22%) 7/14 (50%) 5/16 (31%)
 exanthema 2/13 (15.4%) 11/30 (37%) 7/32 (22%) 8/15 (53%) 2/16 (13%)
 hepatomegaly 0/2 (0%) 9/20 (45%) 2/14 (14%) 1/9 (11%) 1/7 (14%)
 splenomegaly 0/13 (0%) 7/30 (23%) 3/32 (9%) 2/15 (13%) 2/16 (13%)
 serositis 0/13 (0%) 5/29 (17%) 1/31 (3%) 1/15 (7%) 1/16 (6%)
 any systemic manifestation 2 (1.4%) 21/31 (68%) 9/34 (27%) 9/15 (60%) 7/16 (44%)
Disease activity joints
 swollen 114 (79.7%) 21 (57%) 21 (62%) 9 (56%) 19 (51%)
 tender 116 (81.1%) 25 (68%) 21 (62%) 9 (56%) 21 (57%)
 LOM 121 (84.6%) 25 (68%) 27 (79%) 8 (50%) 23 (62%)
 active 120 (83.9%) 24 (65%) 25 (74%) 9 (56%) 22 (59%)
 number of active joints mean +/-SD 9.0 +/- 11.2 5.1 +/- 8.5 5.6 +/- 8.4 2.3 +/- 2.3 3.2 +/- 4.8
 median (IQR) 4.0 (2.0; 11.0) 3.0 (0.0; 6.0) 3.0 (0.3; 7.5) 2.5 (0.0; 4.3) 1.0 (0.0; 4.0)
ESR >20 mm/1 h 107/135 (79.3%) 21 (66%) 12 (55%) 4/8 (50%) 16/31 (52%)
CRP >6 mg/l 113/137 (82.5%) 26 (79%) 18 (64%) 11/15 (73%) 20/34 (59%)
JADAS-10 mean +/- SD (0–14)] 20.7 +/- 9.1 18.8 +/- 10.4 14.2 +/- 10.5 14.2 +/- 9.7 13.0 +/- 9.8
JADAS-10 CRP mean +/- (0–40) 22.2 +/- 9.8 22.3 +/- 11.2 15.3 +/- 9.9 4.3 +/- 10.2 13.4 +/- 10.6
  1. bDMARD biological disease-modifying antirheumatic drug, MTX methotrexate, ESR erythrocyte sedimentation rate, CRP C-reactive protein, JADAS Juvenile Disease Activity Score, LOM limitation of motion